Group 1 - The company reported a revenue of 457 million RMB and a gross profit of 197 million RMB for the six months ending June 30, 2025, with R&D costs amounting to 46.046 million RMB [1] - The hematology testing services saw a steady growth in hospital partnerships, adding over 90 new hospital clients in the first half of 2025, with the pediatric hematology segment adding 48 new cooperative hospitals [1] - The NGS testing IG/TCR rearrangement technology product sales increased by over 50%, showcasing the company's core technological advantages and product features [1] Group 2 - The company emphasized innovation-driven development, with 33 research articles published and 67 patents applied for in the first half of 2025, of which 29 were granted [2] - A total of 56 new R&D testing projects were added during the reporting period, including 16 related to molecular biology testing technology and 16 related to flow cytometry testing technology [2] - The core product in the immune repertoire, used for minimal residual disease detection in hematological malignancies, expanded its coverage to over 160 institutions across 26 provinces, with revenue growth of nearly 30% compared to the same period in 2024 [2]
各项业务均取得稳定进展 康圣环球(09960)发布中期业绩 毛利1.97亿元